8-KLeadership ChangesExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Executive Changes (Feb 10, 2015)

Filed February 10, 2015For Securities:EW

Summary

This Form 8-K filing for Edwards Lifesciences Corporation (EW) on February 10, 2015, primarily announces changes to its Board of Directors. Michael R. Bowlin, a long-standing board member, has decided not to seek re-election at the upcoming 2015 Annual Meeting, signaling a transition in board composition. This departure is presented as a retirement. In parallel, the company has appointed Kieran T. Gallahue to its Board of Directors, effective immediately. Mr. Gallahue brings significant experience from leadership roles at major healthcare companies, including his current position as Chairman and CEO of CareFusion Corporation, and previous executive roles at ResMed, Inc. His appointment is expected to bring valuable expertise to the board, and he will receive standard compensation for non-employee directors.

Key Highlights

  • 1Director Michael R. Bowlin will retire and not seek re-election at the 2015 Annual Meeting.
  • 2Kieran T. Gallahue has been appointed to the Board of Directors, effective immediately.
  • 3Mr. Gallahue brings extensive experience as Chairman and CEO of CareFusion Corporation.
  • 4Previously, Mr. Gallahue served as President and CEO of ResMed, Inc.
  • 5Mr. Gallahue's appointment is expected to enhance the board's expertise in the healthcare sector.
  • 6Mr. Gallahue will receive compensation consistent with other non-employee directors.

Frequently Asked Questions

Michael R. Bowlin has expressed his desire to retire from the Board and will not seek re-election at the Company's 2015 Annual Meeting.

Kieran T. Gallahue, age 51, is the current Chairman and Chief Executive Officer of CareFusion Corporation (since 2011). Prior to that, he was President of ResMed, Inc. from 2004 to 2011, and its Chief Executive Officer from 2008 to 2011.

Mr. Gallahue's appointment to the Board of Directors is significant as he brings substantial leadership experience from prominent companies in the medical technology and healthcare sector, which is expected to benefit Edwards Lifesciences.

No, Mr. Gallahue will receive the same compensation as the Company's other non-employee directors, as detailed in the Company's 2014 Proxy Statement under 'Director Compensation'.